NIX CREME RINSE CREAM

Country: Канада

Језик: Енглески

Извор: Health Canada

Активни састојак:

PERMETHRIN

Доступно од:

INSIGHT PHARMACEUTICALS, LLC

АТЦ код:

P03AC04

INN (Међународно име):

PERMETHRIN

Дозирање:

1%

Фармацеутски облик:

CREAM

Састав:

PERMETHRIN 1%

Пут администрације:

TOPICAL

Јединице у пакету:

56 GM

Тип рецептора:

OTC

Терапеутска област:

SCABICIDES AND PEDICULICIDES

Резиме производа:

Active ingredient group (AIG) number: 0120085001; AHFS:

Статус ауторизације:

APPROVED

Датум одобрења:

2001-02-01

Карактеристике производа

_Product Monograph _
_ _
_Page 1 of 16_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
NIX® CRÈME RINSE
PERMETHRIN CREAM 1%
Topical Pediculicide and Ovicide
ATC Code: P03AC04
Insight Pharmaceuticals LLC
660 White Plains Road, Suite 250
Tarrytown, NY 10591, USA
Date of Initial Authorization:
Apr 29, 2003
Date of Revision:
Dec 6, 2022
Submission Control Number: 263926
®Trademark
_ _
_Product Monograph _
_ _
_ _
_Page 2 of 16_
RECENT MAJOR LABEL CHANGES
1 INDICATIONS, 4 DOSAGE AND ADMINISTRATION
01/2022
TABLE OF CONTENTS
RECENT MAJOR LABEL
CHANGES............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics...........................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 4
4
DOSAGE AND
ADMINISTRATION.................................................................................
4
4.1
Dosing Considerations
.......................................................................................
4
4.2
Recommended Dose and Dosage
Adjustment..................................................... 5
4.3
Reconstitution
...................................................................................................
5
4.4
Administration